The influence of radiation dose on taste impairment in a prospective observational study cohort of oropharyngeal cancer patients

• Published in: Acta oncologica 2022-02, Vol.61 (2), p.146-152
• Main Authors: Stieb, Sonja, Engeseth, Grete M., Mohamed, Abdallah S. R., He, Renjie, Perez-Martinez, Ismael, Rock, Stockton, Deshpande, Tanaya S., Garden, Adam S., Rosenthal, David I., Frank, Steven J., Gunn, G. Brandon, Fuller, C. David
• Format: Article
• Language: English
• Subjects: Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; oropharyngeal cancer; Oropharyngeal Neoplasms - radiotherapy; Prospective Studies; Radiation Dosage; radiotherapy; Taste
• ISSN: 0284-186X; 1651-226X
• DOI: 10.1080/0284186X.2021.2022204

To analyze the influence of radiation dose on late radiation-associated taste impairment in oropharyngeal cancer (OPC) patients treated with intensity-modulated radiotherapy (IMRT) using the taste bud bearing tongue mucosa as organ at risk. This study is part of an ongoing, prospective observational study. Cancer-free OPC survivors with at least 24 months from IMRT were included in this analysis. Scores for taste impairment and dry mouth were extracted from the MD Anderson Symptom Inventory Head and Neck module (MDASI-HN) with scores of ≥5 considered as moderate-to-severe symptoms. The mean dose, minimum and maximum dose to the taste bud bearing tongue mucosa, the ipsi- and contralateral parotid and submandibular glands were extracted and analyzed for correlation with moderate-to-severe taste impairment. One hundred sixteen T1-4 OPC patients were included (81% males, median age: 55). The primary tumor was in the tonsil in 92 cases (79%) and in the base of tongue in 21 cases (18%). Patients were treated with 64.2-72.0 Gy; 37 patients (32%) received concurrent chemotherapy and 22 (19%) concurrent targeted therapy. After a median of 58 months from RT (IQR: 43-68) 38 patients (33%) suffered from moderate-to-severe long-term radiation-associated taste impairment. No dose volume parameter of the taste bud bearing tongue mucosa and the salivary glands was significantly associated with moderate-to-severe taste impairment for the whole patient cohort. For patients without concurrent chemotherapy, the minimum and mean dose to the ipsilateral parotid gland, and the maximum dose to the submandibular gland was significantly associated with late taste impairment (all p